Subcutaneous immunization against Leishmania major - Infection in mice: Efficacy of formalin-killed promastigotes combined with adjuvants;Imunização subcutânea na infecção do camundongo pela Leishmania major: Eficácia dos promastigotos mortos pela formalina combinada com adjuvantes

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 52, Issue 2, 2010, Pages 95-100

  Mutiso, Joshua M ^a   Macharia, John C ^a   Mutisya, Rosemary M ^b   Taracha, Evans ^a  

^a INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^b KENYATTA UNIVERSITY   (Kenya)

Author keywords

Alum; BALB c mice; BCG; Cutaneous leishmaniasis; Formalin killed promastigotes (FKP) promastigotes; Immune responses; Montanide ISA 720 (MISA)

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BCG VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LEISHMANIA VACCINE; PARASITE ANTIGEN; FORMALDEHYDE; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNIZATION; INBRED STRAIN; INTERFERON PRODUCTION; LEISHMANIA MAJOR; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; NONHUMAN; PROMASTIGOTE; SKIN LEISHMANIASIS; SPLEEN LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; MALE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; FORMALDEHYDE; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; LEISHMANIA MAJOR; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MALE; MICE; MICE, INBRED BALB C;

EID: 85047682169     PISSN: 00364665     EISSN: 16789946     Source Type: Journal    
DOI: 10.1590/S0036-46652010000200006     Document Type: Article

References (41)

1. Alimohammadian MH, Darabi H, Kariminia A, Rivier D, Bovay P, Mauel J, et al. Adjuvant effect of Leishmania major promastigotes on the immune response of mice to ovalbumin. Iran Biomed J. 2002;6:123-8.
2. Alving CR. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine. 2002;20(suppl 3):56-64.
3. Bahar K, Dowlati Y, Shidani B, Alimohammadian MH, Khamesipour A, Ehsasi S. et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol. 1996;14:489-95.
4. Bomford R. Aluminium salts: perspectives in their use as adjuvants. In: Gregoriandis G, Allison AC, Poste G, editors. Immunological adjuvants and vaccines. NATO ASI Series A: Life sciences V. 179. Proceedings of a NATO Advanced Study Institute on Immunological Adjuvants and Vaccines, 24 June-5 July 1988, Cape Sounion Beach. New York: Plenum Press, 1989. p. 35-41.
5. Collins WE, Barnwell JW, Sullivan JS, Nace D, Williams T, Boungaseng A, et al. Assessment of transmission-blocking activity of candidate pvs25 vaccine using gametocytes from chimpanzees. Am J Trop Med Hyg. 2006;74:215-21.
6. Convit J, Castellanos PI, Ultrich M, Castes M, Rondon A, Pinardi ME, et al. Immunotherapy of localized, intermediate, and diffuse forms of American cutaneous leishmaniasis. J Infect Dis. 1989;160:104-15.
7. Cook JA, Holbrook TW. Immunogenicity of soluble and particulate antigens from Leishmania donovani: effect of glucan as an adjuvant. Infect Immun. 1983;40:1038-43.
8. Eickhoff TC, Mayers M. Workshop summary: aluminium in vaccines. Vaccine. 2002;20(suppl 3):S1-4.
9. Gicheru MM., Olobo JO, Kariuki TM, Adhiambo C. Visceral leishmaniasis in Vervet monkeys: immunological responses during asymptomatic infections. Scand J Immunol. 1995;41:202-8.
10. Gomez CE, Navea L, Lobaina L, Dubed M, Exposito N, Soto A, et al. The V3 loop based multi-epitope polypeptide TAB9 adjuvated with montanide ISA720 is highly immunogenic in nonhuman primates and induces neutralizing antibodies against five HIV-1 isolates. Vaccine. 1999;17:2311-9.
11. Guirges SY. Natural and experimental re-infection of man with Oriental sore. Ann Trop Med Parasitol. 1971;65:197-205.
12. Holbrook TW, Cook JA. Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes. Am J Trop Med Hyg. 1983,32:51-3.
13. Holbrook TW, Cook JA, Parker BW. Immunization against Leishmania donovani: Glucan as an adjuvant with killed promastigotes. Am J Trop Med Hyg. 1981;30:762-8.
14. Howard JG, Liew FY, Hale C, Nicklin S. Prophylactic immunization against experimental leishmaniasis II. Further characterization of the protective immunity against fatal L. tropica infection induced by irradiated promastigotes. J Immunol. 1984;132:450-5.
15. Kamil AA, Khalil EAG, Musa AM, Modabber F, Mukhtar MM, Ibrahim ME, et al. Alum- precipitated autoclaved Leishmania major plus Bacille Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg. 2003;97:365-8.
16. Kaslow DC, Bathurst IC, Lensen T, Ponnudurai T, Barr PJ, Keister DB. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum. Infect Immun. 1994;62:5576-80.
17. Kenney RT, Edelman R. Survey of human-use adjuvants. Expert Rev Vaccines. 2003;2:167-88.
18. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol. 1999;163:4481-8.
19. Khalil EAG, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. Lancet. 2000;356:1565-9.
20. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res. 2006;123:423-38.
21. Liew FY, Millott S, Li Y, Lelchuck R, Chan WL, Ziltener H. Macrophage activation by interferon-γ from host protective T cells is inhibited by IL-3 and IL-4 produced by disease promoting T cells in Leishmaniasis. Eur J Immunol. 1989;19:1227-32.
22. Macharia JC, Bourdichon AJ, Gicheru MM. Efficacy of trypan: a diminazene based drug as antileishmanial agent. Acta Trop. 2004;92:267-72.
23. Masina S, Gicheru MM, Demotz SO, Fasel NJ. Protection against cutaneous leishmaniasis in outbred Vervet monkeys, using a recombinant histone-1 antigen. J Infect Dis. 2003;188:1250-7.
24. Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK, Katiyar JC, et al. Successful vaccination against Leishmania donovani infection in Indian langur using alum- precipitated autoclaved Leishmania major with BCG. Vaccine 2001;19:3485-92.
25. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol. 1995;89(suppl 1):83-8.
26. Moll H, Martin R. Resistance to murine cutaneous leishmaniasis is mediated by T H l cells, but disease-promoting CD4+ cells are different from TH2 cells. Eur J Immunol. 1990;20:2067-74.
27. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL, et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine. 1999;17:466-72.
28. Musa AM, Khalil EAG, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, et al. Immunochemotherapy of persistent post kala-azar dermal leishmaniasis: a novel approach of treatment. Trans R Soc Trop Med Hyg. 2008;102:58-63.
29. Myriam A, Angelica C, Syed SY, Ahmad RS, Chetan ChE, Rosalie D, et al. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor- binding domain of the Plasmodium vivax duffy binding protein in Aotus monkeys. Am J Trop Med Hyg. 2005;73(suppl 5):25-31.
30. Oliveira GA, Wetzel K, Calvo-Calle JM, Nussenzweig R, Schmidt A, Dubovsky F, et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant montanide ISA 720 in a phase I trial. Infect Immun. 2005;73:3585-97.
31. Olobo JO, Handman E, Curtis JM, Mitchell GF. Antibodies to Leishmania tropica promastigotes during infection in mice of various genotypes. Aust J Exp Biol Med Sci. 1980;58:595-601.
32. Olobo JO, Reid GDF, Githure JI, Anjili CO. IFN-γ and delayed type hypersensitivity are associated with cutaneous leishmaniasis in vervet monkeys following secondary rechallenge with Leishmania major. Scand J Immunol. 1992;36(suppl 11):48-52.
33. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med. 1988;168:1675-84.
34. Serebriakov VA, Karakhodzbaeva SKH, Dzhumaev MD. Effect of leishmanial vaccinations on the dynamics of immunity to diphteria in conditions of secondary revaccination with adsorbed pertussis-diphteria-tetanus vaccine. Med Parazitol. (Mosk.). 1972;41:303-9.
35. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 1998;351:1540-3.
36. Smrkovski LL, Larson CL. Effect of treatment with BCG on the course of visceral leishmaniasis in BALB/c mice. Infect Immun. 1977;16:249-57.
37. Sohrabi Y, Jaafari MR, Mohammadi AM, Eskandari SE, Khamesipour A. Evaluation of immune response against leishmaniasis in resistance C57 BL/6 mice immunized with liposomes containing autoclaved Leishmania major with BCG. Cell Mol Biol Lett. 2005;10:S98.
38. Solbach W, Forberg K, Rollinghoff M. Effect of T-Lymphocyte suppression on the parasite burden in Leishmania major-infected, genetically susceptible BALB/c mice. Infect Immun. 1986;54:909-12.
39. Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun. 1999;67:3719-26.
40. Sypek JP, Chung CL, Mayor SE, Subramanyan JM, Goldman SJ, Sieburth DS, et al. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med. 1993;177:1797-802.
41. Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AST, et al. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with Leishmania major. Infect Immun. 2004;72:5654-61.